Welcome
Welcome to the Theravet investors website,
Here you will find all the financial information dedicated to shareholders and investors
Press releases
05/04/2023 - 07:30
TheraVet continues the assessment of BIOCERA-VET in a new clinical program
04/06/2023 - 07:30
TheraVet launches its Osteosarcoma Reference Centers program
03/28/2023 - 07:30
TheraVet updates on its development and portfolio strategy
12/07/2022 - 07:30
BIOCERA-VET® nominated for the Veterinary Innovation Award (AFVAC 2022)
06/30/2022 - 17:45
TheraVet provides its 2022 first half-year operational update
05/12/2022 - 07:30
General Meeting of June 2, 2022: availability of preparatory documents
03/28/2022 - 07:30
Market-making agreement with Banque Rothschild
03/15/2022 - 07:30
Commercial launch of BIOCERA-VET® in United Kingdom and Ireland
01/25/2022 - 07:30
TheraVet provides its 2021 second half operational update
11/09/2021 - 07:30
TheraVet announces the signing of a research contract with Degroof Petercam
11/03/2021 - 07:30
TheraVet expands its bone substitutes product line
10/21/2021 - 07:30
Commercial launch of BIOCERA-VET® in France and The Netherlands
07/07/2021 - 07:30
TheraVet provides its Half-Year operational update of 2021
06/30/2021 - 07:30
TheraVet announces its 2021 Financial Calendar
06/11/2021 - 18:00
TheraVet: successful IPO on Euronext Growth® Paris et Brussels
04/01/2021 - 07:30
TheraVet announces the commercial launch of BIOCERA-VET
01/26/2021 - 07:30
Positive results in canine cranial cruciate ligament deficiency
11/07/2019 - 07:30